メチシリン耐性黄色ブドウ球菌（MRSA）感染症治療薬の世界市場予測・分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 11
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology 28
3.1.1 MRSA Strains 31
3.1.2 VISA Strains 33
3.1.3 VRSA Strains 33
3.2 Pathophysiology 34
3.2.1 Infection Sites 34
3.2.2 Expression of Virulence Factors 36
3.2.3 Mechanisms of Antibiotic Resistance 38
3.2.4 Biofilm Formation 42
3.3 Symptoms 43
3.4 Prognosis 44
3.4.1 Skin and Soft Tissue Infections 45
3.4.2 Pneumonia 45
3.4.3 Bacteremia 45
3.4.4 Chronic MRSA Infection 46
4 Epidemiology 47
4.1 Disease Background 47
4.2 Risk Factors and Comorbidities 48
4.3 Global Trends 50
4.3.1 US 50
4.3.2 5EU 51
4.3.3 Japan 51
4.4 Forecast Methodology 52
4.4.1 Sources Used 54
4.4.2 Sources Not Used 67
4.4.3 Forecast Assumptions and Methods 68
4.5 Epidemiological Forecast for MRSA (2014-2024) 74
4.5.1 Hospitalized Incident Cases of MRSA 74
4.5.2 Sex-Specific Hospitalized Incident Cases of MRSA 76
4.5.3 Age-Specific Hospitalized Incident Cases of MRSA 78
4.5.4 Age-Standardized Hospitalized Incidence Rate of MRSA 80
4.5.5 Proportion of Hospitalized Incident MRSA Cases by Infection Site 82
4.5.6 Proportion of Hospitalized Incident MRSA Cases by Case Definition 83
4.6 Discussion 84
4.6.1 Epidemiological Forecast Insight 84
4.6.2 Limitations of the Analysis 85
4.6.3 Strengths of the Analysis 86
5 Disease Management 87
5.1 Diagnosis and Treatment Overview 87
5.1.1 Diagnosis 87
5.1.2 Treatment Guidelines 88
5.1.3 Clinical Practice 89
5.2 US 91
5.3 5EU 95
5.4 Japan 98
6 Competitive Assessment 102
6.1 Overview 102
6.2 Product Profiles – Glycopeptides and Lipoglycopeptides 107
6.2.1 Vancomycin 107
6.2.2 Dalvance (dalbavancin) 115
6.2.3 Orbactiv (oritavancin) 124
6.2.4 Vibativ (telavancin) 132
6.2.5 Targocid (teicoplanin) 142
6.3 Product Profiles – Lipopeptides 148
6.3.1 Cubicin (daptomycin) 148
6.4 Product Profiles – Oxazolidinones 157
6.4.1 Zyvox (linezolid) 157
6.4.2 Sivextro (tedizolid phosphate) 169
6.5 Product Profiles – Cephalosporins 178
6.5.1 Teflaro (ceftaroline fosamil) 178
6.5.2 Zevtera (ceftobiprole medocaril) 188
6.6 Product Profiles – Glycylcyclines 197
6.6.1 Tygacil (tigecycline) 197
6.7 Other Antimicrobial Agents 204
7 Unmet Need and Opportunity Analysis 206
7.1 Overview 206
7.2 Drugs with Demonstrated Efficacy in Difficult-to-Treat Patient Populations 209
7.2.1 Unmet Need 209
7.2.2 Gap Analysis 211
7.2.3 Opportunity 212
7.3 Expand Breadth of Clinical Data Outside of Skin Infections 213
7.3.1 Unmet Need 213
7.3.2 Gap Analysis 214
7.3.3 Opportunity 215
7.4 Physician Education 215
7.4.1 Unmet Need 215
7.4.2 Gap Analysis 216
7.4.3 Opportunity 217
7.5 Antibiotics with More Convenient Formulations and Dosing Schedules 218
7.5.1 Unmet Need 218
7.5.2 Gap Analysis 220
7.5.3 Opportunity 221
7.6 Innovative Approaches to Clinical Trial Design 222
7.6.1 Unmet Need 222
7.6.2 Gap Analysis 223
7.6.3 Opportunity 224
7.7 Drugs with Novel Mechanisms of Action 227
7.7.1 Unmet Need 227
7.7.2 Gap Analysis 228
7.7.3 Opportunity 228
7.8 More Affordable Therapies 229
7.8.1 Unmet Need 229
7.8.2 Gap Analysis 230
7.8.3 Opportunity 230
8 Pipeline Assessment 233
8.1 Overview 233
8.2 Promising Drugs in Late-Stage Clinical Development 233
8.2.1 Delafloxacin (RX-3341) 236
8.2.2 Solithromycin (CEM-101) 243
8.2.3 Omadacycline (PTK-0796) 250
8.2.4 KRP-AM1977X 257
8.2.5 Taksta (fusidic acid, oral tablets) 263
8.2.6 Lefamulin (BC-3781) 268
8.2.7 Debio1450 (Debio1452 prodrug) 276
8.2.8 Brilacidin 282
8.3 Other Promising Products in Clinical Development 289
9 Current and Future Players 291
9.1 Overview 291
9.2 Trends in Corporate Strategy 294
9.3 Company Profiles – Current Players 296
9.3.1 Pfizer 296
9.3.2 Merck 298
9.3.3 Allergan 299
9.3.4 The Medicines Company 301
9.3.5 Theravance Biopharma 303
9.3.6 Basilea Pharmaceutica 305
9.3.7 Sanofi 306
9.4 Additional Companies with Promising Pipeline Products 307
9.4.1 Melinta Therapeutics 307
9.4.2 Cempra Pharmaceuticals 308
9.4.3 Paratek Pharmaceuticals 309
9.4.4 Kyorin Pharmaceutical 310
9.4.5 Nabriva Therapeutics 310
9.4.6 Debiopharm International 311
9.4.7 Cellceutix Corporation 311
10 Market Outlook 313
10.1 Global Markets 313
10.1.1 Forecast 313
10.1.2 Drivers and Barriers – Global Issues 321
10.2 US 322
10.2.1 Forecast 322
10.2.2 Key Events 327
10.2.3 Drivers and Barriers 328
10.3 5EU 329
10.3.1 Forecast 329
10.3.2 Key Events 334
10.3.3 Drivers and Barriers 335
10.4 Japan 336
10.4.1 Forecast 336
10.4.2 Key Events 341
10.4.3 Drivers and Barriers 342
11 Appendix 343
11.1 Bibliography 343
11.2 Abbreviations 394
11.3 Methodology 400
11.4 Forecasting Methodology 400
11.4.1 Hospitalized MRSA Patients 400
11.4.2 Percentage of Drug-Treated MRSA Patients 400
11.4.3 Drugs Included in Each Therapeutic Class 401
11.4.4 Launch, Label Expansion, and Patent Expiry Dates 402
11.4.5 General Pricing Assumptions 404
11.4.6 Individual Drug Assumptions 406
11.4.7 Generic Erosion 418
11.4.8 Pricing of Pipeline Agents 418
11.5 Primary Research – KOLs Interviewed for This Report 420
11.6 Primary Research – Prescriber Survey 422
11.7 About the Authors 423
11.7.1 Author and Therapy Area Director 423
11.7.2 Author 423
11.7.3 Epidemiologist 424
11.7.4 Global Director of Therapy Analysis and Epidemiology 424
11.7.5 Global Head of Healthcare 425
11.8 About GlobalData 426
11.9 Disclaimer 426